Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trastuzumab rezetecan - Jiangsu HengRui Medicine Co

Next Previous
Drug Profile

Trastuzumab rezetecan - Jiangsu HengRui Medicine Co

Alternative Names: A1811; SHR-1811; SHR-A1811

Latest Information Update: 04 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Fudan University; Jiangsu Hengrui Medicine Co.; Suzhou Suncadia Biopharmaceuticals
  • Class Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase III Adenocarcinoma; Breast cancer; Colorectal cancer; HER2 positive breast cancer; Ovarian cancer; Triple negative breast cancer
  • Phase II Biliary cancer; Cervical cancer; Gynaecological cancer; Salivary gland cancer; Urogenital cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 01 Sep 2026 Jiangsu HengRui Medicine plans the phase II HORIZON-CRC221 trial for Colorectal cancer (Combination therapy, First-line therapy, Late-stage disease, Inoperable/unresectable, Recurrent, Metastatic disease) in USA (Parenteral, Injection) in November 2026 (NCT07796763)
  • 28 Aug 2026 Phase-III clinical trials in Adenocarcinoma (First-line therapy, Combination therapy, Late-stage disease) in China (Parenteral) (NCT07676162)
  • 28 Aug 2026 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top